Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 199

Sort by

Sort Order Select

Journal Articles

International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations

Blood blood.2024028064.

https://doi.org/10.1182/blood.2024028064

Published: 2025

Includes: Supplemental data

Journal Articles

ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael B Maris, Paolo Ghia, Michael T. Byrne, Nancy L. Bartlett, John Pagel, Yan Zheng, Justyna Kanska, Wangshu Zhang, Enrique Granados, Javier Pinilla-Ibarz

Blood blood.2024027460.

https://doi.org/10.1182/blood.2024027460

Published: 2025

Includes: Supplemental data

Journal Articles

Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q+

Blood blood.2024025102.

https://doi.org/10.1182/blood.2024025102

Published: 2025

Includes: Supplemental data

Journal Articles

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Daniel Sungchul Choi, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Mariia Mikhaleva, Kiyomi Mashima, Rayan Fardoun, Samantha J. Shupe, Stephen Martindale, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

Blood (2024) 144 (Supplement 1): 587.

https://doi.org/10.1182/blood-2024-208951

Published: 2024

Journal Articles

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Blood (2024) 144 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2024-203414

Published: 2024

Journal Articles

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Roberta Santos Azevedo, Mariia Mikhaleva, Kiyomi Mashima, Stephen Martindale, Stacey M. Fernandes, Svitlana Tyekucheva, Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 583.

https://doi.org/10.1182/blood-2024-206576

Published: 2024

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies

Kadriye Nehir Cosgun, Mark E Robinson, Nikol Agadzhanian, Philipp Berning, David Fonseca-Arce, Etienne Leveille, Shalin Kothari, Matthew S. Davids, Julia Jellusova, Markus Müschen

Blood (2024) 144 (Supplement 1): 1412.

https://doi.org/10.1182/blood-2024-208598

Published: 2024

Journal Articles

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

Fen Zhu, Jing Wang, Christine E. Ryan, Liam Hackett, Jeremy Zhang, Stephen Jun Fei Chong, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 1615.

https://doi.org/10.1182/blood-2024-205802

Published: 2024

Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2024-201668

Published: 2024

Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Blood (2024) 144 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2024-208159

Published: 2024

Journal Articles

Orally Bioavailable CDK9 Inhibitor Voruciclib Downregulates Oncogenic Pathways in Leukemic Cells from Patients Treated on a Clinical Trial

Edward C. Dominguez, Carly Roleder, Canping Chen, Zheng Xia, Sandra Wiley, Matthew S. Davids, Alexey Danilov

Blood (2024) 144 (Supplement 1): 721.

https://doi.org/10.1182/blood-2024-198693

Published: 2024

Journal Articles

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Saurabh Yadav, Sumbul Jawed Khan, Binu Kandathilparambil Sasi, Elizabeth F. Cohen, Kiyomi Mashima, Hannah Cormier, Stacey M. Fernandes, Samantha J. Shupe, Roberta Santos Azevedo, Mariia Mikhaleva, Philippe Armand, David C. Fisher, Matthew S. Davids, Inhye E. Ahn, Michael Y. Tolstorukov, Mark A. Murakami, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2024-207527

Published: 2024

Journal Articles

Pharmacodynamic Analysis of Mcl-1 and RNA Pol II Ser2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib

Nathalie Javidi-Sharifi, Jeremy Zhang, Sandra Wiley, Richard G Ghalie, Alexey V. Danilov, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4147.

https://doi.org/10.1182/blood-2024-203689

Published: 2024

Journal Articles

Systems-Based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting

Tariqa Ackbarali, Danielle M. Brander, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 3662.

https://doi.org/10.1182/blood-2024-212306

Published: 2024

Journal Articles

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, Matthew S. Davids, Jeff P. Sharman, Nilanjan Ghosh, Yang Feng, Mary Jean Fusco, Jacqueline Hilger-Rolfe, Chen Qian, Wendy J. Sinai, Sophie Wimberley, John F. Seymour

Blood (2024) 144 (Supplement 1): 6784.

https://doi.org/10.1182/blood-2024-207716

Published: 2024

Journal Articles

Comparative Assessment of Cell Line Models for Optimal Representation of Chronic Lymphocytic Leukemia

Salem Elias, Jeremy Zhang, Ritu Somayaji, Stephanie Chamberlain, Stephen Jun Fei Chong, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 6759.

https://doi.org/10.1182/blood-2024-203777

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Blood (2024) 144 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2024-199577

Published: 2024

Journal Articles

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Blood (2024) 144 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2024-207408

Published: 2024

Journal Articles

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Jennifer L. Crombie, Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Aaron Zou, Samantha Normilus, Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon E. Arnason, Alvaro J Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2024-199234

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations

ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q+

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies

Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Orally Bioavailable CDK9 Inhibitor Voruciclib Downregulates Oncogenic Pathways in Leukemic Cells from Patients Treated on a Clinical Trial

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Pharmacodynamic Analysis of Mcl-1 and RNA Pol II Ser2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib

Systems-Based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Comparative Assessment of Cell Line Models for Optimal Representation of Chronic Lymphocytic Leukemia

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only